49
Participants
Start Date
May 27, 2022
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
Durvalumab 50 MG/1 ML Intravenous Solution [IMFINZI]
"Intravenous infusion of durvalumab 1500 mg on day 1 (induction phase) with carboplatin (AUC 5 on day 1), etoposide (100 mg/sqm on days 1-3) every 3 weeks, and durvalumab (1500 mg on day 1) administered every three weeks for up to 4 cycles (induction phase) or until progression of disease, unacceptable toxicity, patient refusal or loss of clinical benefit (for durvalumab).~Treatment with intravenous durvalumab (1500 mg on day 1) every 4 weeks ± 3 days (maintenance phase) will continue until completion of 24 courses (for a total of 28 courses, including the 4 courses of induction phase) or 2 years of treatment whichever occurs first, disease progression, unacceptable toxicity, patient refusal or loss of clinical benefit."
RECRUITING
AOU Ospedale San Luigi Gonzaga, Orbassano
NOT_YET_RECRUITING
Humanitas Research Hospital, Rozzano
RECRUITING
Ospedale San Gerardo Monza, Monza
NOT_YET_RECRUITING
Centro di riferimento oncologico di Aviano, Aviano
NOT_YET_RECRUITING
Istituto Oncologico Veneto IRCCS-IOV, Padua
RECRUITING
IRCCS AOU Policlinico Sant'Orsola Malpighi, Bologna
NOT_YET_RECRUITING
Azienda Ospedaliera Universitaria di Parma, Parma
NOT_YET_RECRUITING
"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - IRST S.r.l. IRCCS", Meldola
NOT_YET_RECRUITING
Azienda Ospedaliera Universitaria Careggi, Florence
NOT_YET_RECRUITING
Azienda Usl Toscana nord ovest Ospedale San Luca, Lucca
NOT_YET_RECRUITING
Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari, Bari
NOT_YET_RECRUITING
"A.O.R.N. A. Cardarelli", Napoli
NOT_YET_RECRUITING
Istituto Oncologico del Mediterraneo IOM - Viagrande Catania, Viagrande
NOT_YET_RECRUITING
Azienda Ospedaliera San Camillo Forlanini-Ospedale San Camillo, Roma
NOT_YET_RECRUITING
AOU Sassari - Ospedale SS. Annunziata, Sassari
Gruppo Oncologico Italiano di Ricerca Clinica
OTHER